Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

223.19 -3.41 (-1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 812,592
Open 225.48
Bid (Size) 220.05 (1)
Ask (Size) 223.10 (1)
Prev. Close 226.60
Today's Range 222.83 - 229.53
52wk Range 189.44 - 287.60
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire

Performance

YTD
-16.63%
-16.63%
1 Month
+2.04%
+2.04%
3 Month
+3.00%
+3.00%
6 Month
-14.39%
-14.39%
1 Year
-20.74%
-20.74%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
Via MarketBeat
Exposures Product Safety
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
From Robbins Geller Rudman
Via Business Wire
The 3 Best Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via GlobeNewswire
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
Via InvestorPlace
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Via FinancialNewsMedia
Exposures Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Via Benzinga
Exposures Product Safety
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Via Investor's Business Daily
Exposures Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
BIIB Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Biogen Inc.
From Robbins LLP
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biogen Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.